Acalabrutinib CYP3A mediated Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to inform dose adjustment strategy.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15278
Abstract: AIMS Clinical drug interaction studies with itraconazole and rifampicin demonstrated acalabrutinib is a sensitive substrate of CYP3A. A PBPK model was developed based on the data of these studies. One of the active CYP3A metabolite… read more here.
Keywords: study; drug; cyp3a; acp 5862 ... See more keywords